Top Page
Smith & Nephew Snats
(NYSE:SNN)
Smith & Nephew Snats (SNN) vs. SPDR S&P 500 ETF (SPY)
Smith & Nephew Snats Business Overview & Revenue Model
Smith & Nephew Snats Key Performance Indicators (KPIs)
Analyzes revenue contributions from different business units, indicating which segments are leading growth and how diversified the company's income streams are.
Main Street DataSmith & Nephew Snats Earnings Call Summary
Smith & Nephew Snats Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.97B | 5.81B | 5.55B | 5.21B | 5.21B | 4.56B |
| Gross Profit | 4.18B | 4.05B | 3.82B | 3.67B | 3.67B | 3.16B |
| EBITDA | 1.44B | 1.24B | 979.00M | 943.00M | 1.24B | 866.00M |
| Net Income | 493.64M | 412.00M | 263.00M | 223.00M | 524.00M | 448.00M |
Balance Sheet | ||||||
| Total Assets | 10.68B | 10.35B | 9.99B | 9.97B | 10.92B | 11.01B |
| Cash, Cash Equivalents and Short-Term Investments | 675.41M | 619.00M | 302.00M | 350.00M | 1.29B | 1.76B |
| Total Debt | 3.45B | 3.32B | 3.08B | 2.87B | 3.34B | 3.69B |
| Total Liabilities | 5.15B | 5.09B | 4.77B | 4.71B | 5.35B | 5.73B |
| Stockholders Equity | 5.53B | 5.26B | 5.22B | 5.26B | 5.57B | 5.28B |
Cash Flow | ||||||
| Free Cash Flow | 799.32M | 606.00M | 181.00M | 110.00M | 469.00M | 492.00M |
| Operating Cash Flow | 1.15B | 987.00M | 608.00M | 468.00M | 877.00M | 935.00M |
| Investing Cash Flow | -345.22M | -569.00M | -448.00M | -472.00M | -691.00M | -606.00M |
| Financing Cash Flow | -676.96M | -86.00M | -200.00M | -926.00M | -645.00M | 1.16B |
Smith & Nephew Snats Technical Analysis
Smith & Nephew Snats Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $23.23B | 35.76 | 9.73% | 0.99% | 2.47% | 63.68% | |
73 Outperform | $15.00B | 31.06 | 9.20% | 2.14% | 5.78% | 61.52% | |
73 Outperform | $18.76B | 23.06 | 6.52% | 1.01% | 4.11% | -14.43% | |
73 Outperform | $7.64B | 21.83 | 8.62% | ― | 17.43% | 775.48% | |
71 Outperform | $22.14B | 95.72 | 19.18% | ― | 25.99% | -40.46% | |
56 Neutral | $26.20B | ― | -7.10% | 3.24% | -0.76% | -55.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Smith & Nephew Snats Corporate Events
Smith & Nephew plc, a company listed on the London Stock Exchange, announced its total issued share capital as of September 30, 2025. The company reported that it has 877,724,845 ordinary shares, with 24,102,908 held in treasury, resulting in 853,621,937 shares with voting rights. This information is crucial for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
Smith+Nephew announced that its Chief Financial Officer, John Rogers, will relocate to the United States effective September 29, 2025, to enhance leadership and oversight in the region, which contributes significantly to the company’s revenue. This move aligns with the company’s strategy to focus on the US market, allowing closer collaboration with senior leaders and supporting the execution of business strategies. Rogers’ remuneration will be adjusted to align with US market practices, with changes to his base salary, pension cash allowance, and performance-related awards.
On September 8, 2025, Smith & Nephew plc reported the sale of ordinary shares by Alison Parkes, the Chief Compliance Officer, on the London Stock Exchange. This transaction, disclosed in accordance with the UK Market Abuse Regulation, highlights the company’s commitment to transparency in its financial dealings, potentially impacting investor perceptions and market positioning.
On September 9, 2025, Smith & Nephew announced a transaction involving the sale of ordinary shares by Vasant Padmanabhan, President of Research & Development ENT, who is classified as a Person Discharging Managerial Responsibilities (PDMR). The transaction, conducted outside the trading venue, involved the sale of 17,643 shares at a price of £14.25 each. This announcement is made in compliance with the UK Market Abuse Regulation, highlighting the company’s commitment to transparency in its financial dealings.
Smith & Nephew plc, a company involved in the healthcare industry, announced on September 1, 2025, that its total issued share capital as of August 31, 2025, consists of 877,718,356 ordinary shares, with 6,748,465 held in treasury. This results in a total of 870,969,891 voting shares, which shareholders should use as a reference for notifying changes in their interest under FCA rules.
On August 27, 2025, Smith & Nephew plc announced the granting of performance and restricted share awards to Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, under the Global Share Plan 2020 and Restricted Share Plan 2024. These awards, which are based on the company’s share price on the London Stock Exchange, are part of the company’s incentive strategy to align managerial interests with shareholder value and ensure long-term commitment from key personnel.
On August 28, 2025, Smith+Nephew announced the appointment of Dr. Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective September 1, 2025. Dr. Kong brings extensive experience in the medtech and biopharma sectors, having held various executive and non-executive roles, which is expected to enhance the company’s strategic direction and innovation capabilities.
On August 22, 2025, Smith & Nephew plc executed a share purchase transaction as part of its remuneration policy to compensate Non-Executive Directors with shares instead of cash for part of their annual fees. This move, disclosed on August 26, 2025, aligns with the UK Market Abuse Regulation and reflects the company’s strategic approach to align director interests with shareholder value, potentially impacting its governance and stakeholder relations.
On August 20, 2025, Sybella Stanley, a Non-Executive Director at Smith & Nephew plc, purchased 1,520 ordinary shares of the company on the London Stock Exchange. This transaction was part of the company’s policy to compensate its non-executive directors partially in shares, reflecting a strategic alignment of management interests with shareholder value.
On August 18, 2025, Smith & Nephew plc announced the partial vesting of awards under its Restricted Share Plan 2024, with some shares sold to cover tax obligations. Additionally, David King, a Non-Executive Director, purchased American Depository Receipts on the New York Stock Exchange, reflecting confidence in the company’s market position.
On August 12, 2025, Smith & Nephew plc announced the partial vesting of share awards under its Global Share Plan 2020. These awards, initially granted on August 11, 2023, will vest in equal tranches over three years. The recent vesting led to some shares being sold to cover tax obligations, impacting the company’s share distribution and potentially influencing stakeholder perceptions of executive compensation strategies.
On August 1, 2025, BlackRock, Inc. adjusted its holdings in Smith & Nephew PLC, a UK-based company, by acquiring or disposing of voting rights. The change resulted in BlackRock holding 6.61% of the voting rights, down from a previous 6.83%. This adjustment in holdings could influence Smith & Nephew’s shareholder dynamics and potentially impact its strategic decisions.
On August 5, 2025, Smith & Nephew plc experienced a change in its voting rights structure due to an acquisition or disposal by BlackRock, Inc. The transaction resulted in BlackRock holding 6.76% of the total voting rights, up from a previous 6.61%. This adjustment in holdings could influence Smith & Nephew’s shareholder dynamics and potentially impact its strategic decisions moving forward.
On August 6, 2025, Elga Lohler, Chief HR Officer of Smith & Nephew plc, sold ordinary shares of the company on the London Stock Exchange. This transaction was publicly disclosed in compliance with the UK Market Abuse Regulation, highlighting transparency in managerial dealings which could impact stakeholder trust and market perception.
Smith & Nephew reported strong financial results for the second quarter and first half of 2025, with significant revenue growth and improved profitability. The company announced a $500 million share buyback, reflecting strong cash generation and a solid balance sheet. Revenue growth was driven by new product launches and operational improvements, with all regions and business units contributing positively. The company maintained its full-year guidance, expecting continued revenue growth and trading profit margin expansion.
Smith+Nephew announced on August 5, 2025, a share buyback program to return $500 million to shareholders, reflecting strong cash generation and a robust balance sheet from its 12-Point Plan transformation. The program, running from August 5 to December 31, 2025, involves repurchasing shares through J.P. Morgan Securities, with the intent to reduce issued share capital and return surplus capital to shareholders, without affecting growth plans.
On August 5, 2025, Smith & Nephew announced its second quarter and first half 2025 financial results, showcasing strong revenue growth, trading margin expansion, and improved cash flow. The company reported a 7.8% increase in second-quarter revenue and a 4.7% rise in half-year revenue compared to the previous year. Operating profit surged by 30.6%, and the company generated $244 million in free cash flow. Smith & Nephew also announced a $500 million share buyback, reflecting strong cash generation and a robust balance sheet. The company maintained its full-year guidance, expecting underlying revenue growth of around 5.0% and trading profit margin expansion. Recent product launches have driven growth across all business units, contributing significantly to the company’s financial performance.
On August 1, 2025, Smith & Nephew plc announced its total issued share capital as of July 31, 2025, which comprises 877,710,150 ordinary shares, including 1,748,679 held in treasury. This announcement is crucial for shareholders as it determines the denominator for notifying changes in their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
Smith+Nephew announced that it will release its second quarter and first half 2025 financial results on August 5, 2025. This announcement is significant as it provides insights into the company’s financial performance and strategic positioning in the medical technology industry. The results will be followed by a conference call for financial analysts, highlighting the company’s commitment to transparency and engagement with stakeholders.
On July 10, 2025, Smith & Nephew plc reported transactions involving the purchase of American Depository Shares by key executives as part of the company’s Employee Stock Purchase Plan. This notification, made in compliance with the UK Market Abuse Regulation, highlights the involvement of top management in the company’s stock, potentially indicating confidence in the company’s future performance and aligning management interests with those of shareholders.